Before any drug reaches the market or even moves to large-scale testing, it has to pass one critical checkpoint: Phase 1. This is where it all begins.
For sponsors and CROs, Phase 1 trials set the foundation for everything that follows. They’re high-stakes, time-sensitive, and tightly regulated. Small mistakes here can delay entire development programs or compromise safety data.
Phase 1 clinical trials are designed to answer one key question: Is the investigational product safe for humans? But behind that simple goal lies complex planning, strict oversight, and constant risk management.
In this blog, we’ll break down what Phase 1 trials involve, why they matter, and how sponsors and CROs can execute them with speed, accuracy, and compliance.
TL;DR
- Phase 1 clinical trials assess the safety, dosage, and tolerability of investigational products in humans, typically for the first time.
- These trials include a small number of healthy volunteers or patients and focus on pharmacokinetics (PK), pharmacodynamics (PD), and adverse events.
- Common designs include single ascending dose (SAD), multiple ascending dose (MAD), and food-effect studies.
- Key challenges include tight timelines, regulatory complexity, patient safety, and real-time data needs.
- Success depends on streamlined trial setup, experienced monitoring teams, early risk mitigation, and integrated data oversight.
- DRK Research Solutions offers full-service Phase 1 trial execution with site startup, regulatory support, safety monitoring, and data integration.
What Is a Phase 1 Clinical Trial?
A Phase 1 trial is the first step in testing a new drug or therapy in humans. The main goal is to assess safety, tolerability, and how the drug behaves in the body.
These trials usually involve 20 to 100 participants, often healthy volunteers, though patients may be included for oncology or other high-risk areas. Dosing starts low and increases gradually to identify side effects, dose-limiting toxicities, and PK/PD profiles.
Common types of Phase 1 studies include:
- Single Ascending Dose (SAD): Increasing doses are given once to different cohorts to find the maximum tolerated dose.
- Multiple Ascending Dose (MAD): Repeated doses over time to study accumulation and extended tolerability.
- Food-Effect Studies: Determine how food intake impacts the absorption or metabolism of the drug.
Data from Phase 1 forms the backbone of dosing decisions in Phase 2 and informs both safety protocols and study designs moving forward.
What Phase 1 Trials Are Really Trying to Find Out?
At its core, a Phase 1 trial is about one thing: safety. It’s the first time a new drug is tested in people, so everything centers around understanding how the body responds and how far you can go safely.
Here’s what teams are focused on during this phase:
1. Is It Safe to Use in People?
This is the big one. Every dose is closely monitored for side effects or any unexpected events. The goal is to figure out what’s tolerated and where the limits are, without putting anyone at risk.
2. How Does the Body Process the Drug?
This is all about pharmacokinetics (PK). Sponsors track how the drug moves through the body, how fast it’s absorbed, where it goes, how it breaks down, and how long it stays in the system.
3. Is the Drug Doing Anything Biologically?
Sometimes Phase 1 includes early pharmacodynamic (PD) measures like changes in enzyme levels, blood pressure, or biomarkers. These clues help link dose levels to biological activity, even if there’s no focus on treatment results yet.
4. What Dosing Strategy Makes Sense Moving Forward?
Single and multiple dose data help define how the drug should be given later on, starting doses, escalation steps, and how food or other variables might affect absorption.
5. Can This Data Support a Move to Phase 2?
Everything collected here has to hold up to regulatory review. That means clean safety data, validated methods, and clear documentation across every step.
When Phase 1 is done right, sponsors and CROs walk away with confidence and a clear path forward.
How Phase 1 Trials Are Designed?
Designing a Phase 1 trial isn’t just about getting the protocol approved. It’s about building a framework that keeps participants safe, delivers clean data, and avoids delays that cost time and budget.
Here’s what goes into it:
| Design Element | What to Consider |
| Study Population | Healthy volunteers or patients, depending on risk and indication. |
| Dosing Strategy | SAD, MAD, and food-effect models to assess safety, tolerability, and drug behavior. |
| Safety Monitoring | Real-time AE tracking, cohort pauses, and clear dose-escalation rules. |
| PK/PD Sampling Plan | Precise blood draw timing to evaluate absorption, metabolism, and biological impact. |
| Regulatory Compliance | Protocols aligned with FDA, EMA, and ICH guidance to ensure approval readiness. |
Common Challenges in Phase 1 Trials
Phase 1 moves fast. But speed doesn’t mean simple. These trials come with a unique set of risks, and getting ahead of them can make the difference between clean execution and costly delays.
Here’s what sponsors and CROs run into most often:
1. Timelines Are Tight
Start-up timelines in Phase 1 are often aggressive. Delays in approvals, site setup, or logistics can throw off the entire development plan.
2. Safety Oversight Can’t Slip
Since it’s the first time the drug is in humans, there’s no room for error. One missed signal can compromise both safety and data integrity.
3. Recruitment Isn’t Always Easy
Even with small cohorts, finding healthy volunteers or the right patients in therapeutic trials can stall progress.
4. Data Has to Be Clean and Fast
Regulators expect complete, timely data. In Phase 1, messy data or delayed reporting can prevent dose escalation or trigger audit risk.
5. Budget Pressures Are Real
Phase 1 might be short, but the costs add up quickly, especially with repeat cohorts, protocol amendments, or supply chain delays.
Phase 1 Trial Success: What Sponsors Should Focus On?
Running a Phase 1 trial requires balancing risk, speed, and precision. With short timelines, close safety oversight, and strict regulatory expectations, there is little room for error.
Here’s what sponsors and CROs should focus on to get it right:
1. Define Clear Objectives Up Front
Know exactly what you need to learn, whether it’s safety, PK, food effect, or biomarker response. Trying to collect too much data can slow down the study and complicate analysis.
How to do it: Work with cross-functional teams to align on the most critical endpoints. Focus the protocol on must-have data only.
2. Choose Sites With Phase 1 Experience
Not all sites are built for early-phase research. You need teams familiar with dose escalation, PK sampling, and safety event tracking.
How to do it: Pre-screen sites based on their experience, set up timelines, and lab handling processes. Run startup and training in parallel where possible.
3. Streamline Regulatory and Ethics Submissions
Delays during approval are common but often avoidable. A strong submission strategy reduces review cycles and keeps timelines intact.
How to do it: Use submission templates, assign a dedicated regulatory contact, and align your documents with current ICH and FDA expectations.
4. Implement Real-Time Safety and Data Oversight
Waiting for weekly or manual data reports can delay dose escalation and slow decision-making.
How to do it: Use integrated data systems and dashboards for live tracking. Set fixed internal reviews between cohorts to keep things moving.
5. Keep Participants Engaged and Informed
Even small trials are impacted by missed visits or dropouts. A good participant experience improves both retention and data quality.
How to do it: Provide clear instructions, regular reminders, and responsive on-site support for any questions or concerns.
6. Plan for Contingencies
Unexpected issues happen, whether it’s supply delays, protocol changes, or shifts in recruitment.
How to do it: Build buffer time into your plan and work with partners who can adapt quickly without stalling progress.
How DRK Research Solutions Supports Clinical Trials
DRK Research Solutions provides full-service support for clinical trials with a focus on speed, data accuracy, and global regulatory compliance. Our team works closely with sponsors and CROs to manage complex protocols, high-volume data, and cross-functional trial execution.
- Comprehensive Trial Management: We manage everything from protocol design and site feasibility to study start-up, monitoring, and clinical study report (CSR) delivery.
- Experienced Site and Investigator Network: We work with established clinical sites equipped to handle complex studies with strict safety and data requirements.
- Integrated Data Systems: Our eClinical platforms support centralized data capture, safety oversight, and real-time reporting, helping sponsors respond quickly and stay audit-ready.
- Regulatory and Ethics Support: We prepare and manage submissions aligned with FDA, EMA, and ICH standards to keep studies moving with fewer approval delays.
- Hybrid Monitoring Model: Our combination of on-site and in-house monitors improves data quality and accelerates issue resolution.
- Global + Local Operations: With presence in Asia, Europe, and emerging markets, we offer fast startup, regional insight, and consistent execution across geographies.
Conclusion
Phase 1 is where the clinical journey begins, and it carries more weight than most realize. It’s where safety is established, data systems are tested, and trial teams face the pressure of tight timelines and high scrutiny.
For sponsors and CROs, success at this stage comes down to preparation, speed, and execution. The more tightly designed and well-supported the trial, the faster you move forward with confidence.
At DRK Research Solutions, we help sponsors run trials that move fast, stay controlled, and meet global regulatory standards, without sacrificing data quality or patient safety.
Ready to Simplify Trial Execution? Contact DRK Research Solutions today and learn how our global teams and digital systems support smoother trial execution.
FAQs
1. What is the main goal of a Phase 1 clinical trial?
The primary goal is to evaluate safety, tolerability, and how the drug behaves in the human body. It’s the first step in testing a new compound in people.
2. Who typically participates in Phase 1 trials?
Most Phase 1 trials enroll healthy volunteers. However, in therapeutic areas like oncology, early trials often include patients with the target condition.
3. How long does a Phase 1 trial usually take?
Most studies last a few weeks to a few months, depending on the design. Timelines vary based on the number of cohorts and data review requirements.
4. What happens if safety issues are found?
If adverse events occur, dosing may be paused, or the study may be stopped. The sponsor, investigators, and ethics committees continuously review safety.
5. What types of data are collected in Phase 1?
Common data includes vital signs, lab results, pharmacokinetics (PK), pharmacodynamics (PD), and adverse events—all used to support decisions for future trials.